Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ROE | 42.88 | 0.31 | +0.72% |
| Astoria US Equal Weight Quality Kings ETF (ROE) | |||
| SMMU | 49.41 | N/A | N/A |
| PIMCO Short Term Municipal Bond Active ETF (SMMU) | |||
| DRGN | 31.93 | -0.18 | -0.57% |
| Themes China Generative Artificial Intelligence ETF (DRGN) | |||
| PGJ | 21.70 | -0.24 | -1.09% |
| Invesco Golden Dragon China ETF (PGJ) | |||
| KBDU | 10.07 | -0.33 | -3.18% |
| KraneShares 2x Long BIDU Daily ETF (KBDU) | |||
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | -0.72% | ||
| VCYT - XNCR | 52% Loosely correlated | -4.02% | ||
| KURA - XNCR | 50% Loosely correlated | -0.56% | ||
| MLTX - XNCR | 49% Loosely correlated | -1.97% | ||
| RCUS - XNCR | 48% Loosely correlated | -2.32% | ||
| VIR - XNCR | 46% Loosely correlated | +0.98% | ||
More | ||||
XNCR saw its Momentum Indicator move above the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 58 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 195 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for XNCR moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 16 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 54 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for XNCR turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
XNCR broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.782) is normal, around the industry mean (26.780). P/E Ratio (72.464) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.